RecruitingACTRN12605000037606
NIVOAD Study: Non Invasive Ventilation in Obstructive Airways Diseases Study
NIVOAD Study: Non Invasive Ventilation duration in Obstructive Airways Diseases Study
Sponsor
Dr Anthony Cross
Enrollment
192 participants
Start Date
Jun 1, 2005
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Inclusion Criteria1
- All patients presenting to participating EDs with moderate to severe exacerbations of obstructive airways disease and judged by the clinical staff as requiring NIV. Criteria for this judgement include RR >23, SaO2 <90% on room air or <93% on 15 lpm via Hudson mask or an inability to speak in sentences.
Exclusion Criteria1
- Obtundation (to the point of being unable to cooperate or protect the airway), primary cause of respiratory failure other than asthma or COAD, untreated pneumothorax, endotracheal intubation and a decision to withhold or withdraw treatment made by the clinician in consultation with the patient or next of kin.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
CPAP vs BiPAP The duration is unknown but it is estimated to be in the order of 120 minutes
CPAP vs BiPAP The duration is unknown but it is estimated to be in the order of 120 minutes
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000037606
Related Trials
Giving Asthmatics Intramuscular Steroids for Preventing Return to the Emergency Department
NCT072280521 location
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
NCT070739507 locations
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
NCT0755615954 locations
Personalized Environment and Genes Study
NCT003412372 locations
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589143 locations